Donor-derived microbial engraftment and gut microbiota shifts associated with weight loss following fecal microbiota transplantation
Applied and Environmental Microbiology · 23.07.2025 · 91 (7)
DOI: 10.1128/aem.00120-25 ↗Kurz gefasst
Klinische Studie in der Zeitschrift Applied and Environmental Microbiology, erschienen am 23.07.2025. Verfasst von Yuting Ruan und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology and Metabolism, Zhujiang Hospital, Southern Medical University, Guangzhou, China. Hauptthemen laut MEDLINE: Fecal Microbiota Transplantation, Gastrointestinal Microbiome, Obesity, Weight Loss. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Guangdong Province, Science and Technology Program of Guangzhou.
Abstract (Originalsprache)
Fecal microbiota transplantation (FMT) is a promising treatment for microbiota dysbiosis and may provide metabolic benefits for obesity. However, its mechanisms and variability in clinical outcomes remain poorly understood. This 12-week multicenter, single-arm study evaluated the efficacy of FMT for weight loss and explored the role of donor-derived microbial engraftment and functional shifts in mediating weight loss among overweight and obese individuals. Twenty-three participants (body mass index ≥24 kg/m²) without diabetes received three biweekly FMT sessions via a nasojejunal tube. Fecal samples from participants and donors were analyzed using metagenomic sequencing. By week 12, 52% of participants were classified as responders, achieving significant weight loss of ≥5% from baseline, with an average weight loss of 7.98 ± 2.69 kg ( P < 0.001). In contrast, non-responders lost 2.90 ± 1.89 kg ( P < 0.001). Responders exhibited a significantly higher proportion of donor-derived microbial strains post-FMT compared to non-responders (37.8% vs 15.2%, P = 0.020). Notably, key taxa, including Phascolarctobacterium ( P = 0.034) and Acidaminococcaceae ( P = 0.012), increased significantly in abundance in responders post-FMT, indicating successful microbial engraftment as a critical determinant of therapeutic success. These findings suggest that FMT is a viable intervention for weight loss in obese individuals. Successful donor-derived microbial engraftment strongly correlates with weight loss efficacy, highlighting the potential of microbiota-targeted therapies in obesity management and providing insights into the mechanisms underlying FMT outcomes. IMPORTANCE Prior research indicates that fecal microbiota transplantation (FMT) is a promising treatment for diseases related to microbiota imbalance, potentially providing metabolic benefits for obesity. However, the specific role of donor-derived microbial engraftment in driving clinical efficacy has remained unclear. In this study, we evaluated the efficacy of FMT in promoting weight loss and explored the role of donor-derived bacterial strains in this process. Our findings demonstrate that the successful engraftment of specific donor-derived taxa, such as Phascolarctobacterium and Acidaminococcaceae , is strongly associated with significant weight loss. This highlights the critical interplay between donor microbiota and recipient gut environment. These findings underscore the potential of microbiota-targeted therapies as a novel strategy for obesity management. CLINICAL TRIALS This study is registered with the Chinese Clinical Trial Registry as ChiCTR1900024760 .
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Endocrinology and Metabolism, Zhujiang Hospital, Southern Medical University, Guangzhou, China.
- Southern Medical University, Guangzhou, China.
- Department of Endocrinology, Suixi Country People's Hospital, Guangdong Medical University, Guangzhou, China.
- Department of Endocrinology, Shenzhen Hengsheng Hospital, Shenzhen, China.
- Department of Endocrinology, Wengyuan Country People's Hospital, Shaoguan, China.
- Department of Endocrinology, The First People's Hospital of Zhaoqing, Zhaoqing, China.
ORCID-Profile: Yuting Ruan, Tongxi Zhu, Hong Chen, Rongping Chen
Förderung
- National Natural Science Foundation of China
- Natural Science Foundation of Guangdong Province
- Science and Technology Program of Guangzhou
Zitieren
APA
Ruan, Y., Zhu, T., Yang, R., Su, F., An, C., Hu, Z., Li, X., Li, Y., Chen, P., Shao, X., Qin, J., Chen, H., & Chen, R. (2025). Donor-derived microbial engraftment and gut microbiota shifts associated with weight loss following fecal microbiota transplantation. Applied and Environmental Microbiology, 91(7). https://doi.org/10.1128/aem.00120-25
Vancouver
Ruan Y, Zhu T, Yang R, Su F, An C, Hu Z, et al. Donor-derived microbial engraftment and gut microbiota shifts associated with weight loss following fecal microbiota transplantation. Applied and Environmental Microbiology. 2025;91(7). doi:10.1128/aem.00120-25
BibTeX
@article{Ruan2025,
author = {Ruan, Yuting and Zhu, Tongxi and Yang, Rui and Su, Fugui and An, Chiying and Hu, Zhuping and Li, Xiaoli and Li, Yue and Chen, Peizhao and Shao, Xueni and Qin, Junjie and Chen, Hong and Chen, Rongping},
title = {Donor-derived microbial engraftment and gut microbiota shifts associated with weight loss following fecal microbiota transplantation},
journal = {Applied and Environmental Microbiology},
year = {2025},
volume = {91},
number = {7},
doi = {10.1128/aem.00120-25}
}
EUVIMED